Japan approves subcutaneous autoinjector form of Leqembi for Alzheimer's

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/21/2026

1. SPCX
2. NVDA
3. NFLX
4. ISRG
5. RTX
6. COF
7. SMCI
8. GOOGL
9. TSLA
10. CRWV

Go back to Japan approves subcutaneous autoinjector form of Leqembi for Alzheimer's

Leqembi® Pen subcutaneous formulation approved in Japan

September 16, 2026 2:15 AM EDT

STOCKHOLM, Sept. 16, 2026 /PRNewswire/ -- BioArctic AB (publ)'s (NASDAQ STOCKHOLM: BIOA B) partner Eisai announced today that the subcutaneous autoinjector formulation of Leqembi (known as Leqembi Pen in Japan) has been approved as a new route of administration for the treatment of early Alzheimer's disease.

Leqembi Pen enables patients or care partners to self-administer treatment, with two injections... More